Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 2 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - suspension for inhalation - fluticasone propionate 250 mcg/dose - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - suspension for inhalation - fluticasone propionate 125 mcg/dose - fluticasone - fluticasone - prophylactic management of all grades of asthma.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - suspension for inhalation - fluticasone propionate 50 mcg/dose - fluticasone - glucocorticoids - prophylactic management of all grades of asthma.children aged 1 to 4 years:inhaled fluticasone propionate is of benefit to young children in the control of persistent asthma

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water - canesoral fluconazole capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; clotrimazole 10 mg/g - combination - 150mg & 10mg/g - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water active: clotrimazole 10 mg/g excipient: benzyl alcohol cetostearyl alcohol cetyl palmitate octyldodecanol polysorbate 60 purified water sorbitan stearate - vaginal candidiasis. cream can be used for relief of external itching/irritation and the management of candida vulvovaginitis or infection of the peri-anal area.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - micafungin 100mg - powder for injection - 100 mg - active: micafungin 100mg excipient: citric acid lactose nitrogen sodium hydroxide - treatment of invasive candidiasis in children & adults treatment of oesophageal candidiasis in adults, adolescents nlt 16 yrs of age, and elderly patients for whom intravenous therapy is appropriate prophylaxis of candida infection in children and adult patients undergoing allogenic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count below 500 cells per microliter) for 10 or more days

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - micafungin 50mg - powder for injection - 50 mg - active: micafungin 50mg excipient: citric acid lactose nitrogen sodium hydroxide - treatment of invasive candidiasis in children & adults treatment of oesophageal candidiasis in adults, adolescents nlt 16 yrs of age, and elderly patients for whom intravenous therapy is appropriate prophylaxis of candida infection in children and adult patients undergoing allogenic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count below 500 cells per microliter) for 10 or more days

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - posaconazole 100mg - modified release tablet - 100 mg - active: posaconazole 100mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry ii yellow 85f92209 - indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: - invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole. - oesophageal candidiasis or candidemia in patients with disease that is refractory to, or who are intolerant of, amphotericin b, fluconazole, or itraconazole. - fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. - coccidioidomycosis noxafil tablets are also indicated for use as: - prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients 13 years of age and older who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriconazole wockhardt is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.